- Trials with a EudraCT protocol (10,882)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10,882 result(s) found for: Pregnancy.
Displaying page 174 of 545.
EudraCT Number: 2014-004078-40 | Sponsor Protocol Number: CQR14002 | Start Date*: 2015-01-28 | |||||||||||
Sponsor Name:CeQur Corp. | |||||||||||||
Full Title: A Prospective, Single Center, Observational Study to Assess the Performance, Safety, and Patient Reported Outcomes of Insulin Delivery with PaQ® in Patients with Type 2 Diabetes Mellitus | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001911-31 | Sponsor Protocol Number: 30032006 | Start Date*: 2007-06-27 | |||||||||||
Sponsor Name:Universitätsfrauenklinik Innsbruck | |||||||||||||
Full Title: Metformin-Wirkung am Ovar bei PCOS (MAO-Studie) - eine Pilotstudie | |||||||||||||
Medical condition: Polycystic ovary syndrome is one of the most common endocrine disorders, affecting approximately 10% of women of reproductive age, associated with hyperandrogenaemia and menstrual dysfunction. The ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000181-21 | Sponsor Protocol Number: BUCSU | Start Date*: 2014-07-02 | |||||||||||
Sponsor Name:Charite - Universitätsmedizin Berlin | |||||||||||||
Full Title: Disease activity controlled dose escalating study to assess the efficacy, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in chronic spontaneous urticaria. | |||||||||||||
Medical condition: Chronic Spontaneous Urticaria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003638-28 | Sponsor Protocol Number: 2015/576 | Start Date*: 2015-09-30 | ||||||||||||||||
Sponsor Name:Aarhus University Hospital | ||||||||||||||||||
Full Title: ALOSTRA Alendronate treatment of osteoporosis in rheumatoid arthritis – indication and duration. A randomized, doubleblind, placebocontrolled multi-centre study to evaluate the effects of disconti... | ||||||||||||||||||
Medical condition: Rheumatoid arthritis and osteoporosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003089-16 | Sponsor Protocol Number: AGO-OVAR2.11 | Start Date*: 2007-08-31 |
Sponsor Name:AGO Research GmbH | ||
Full Title: Phase II trial in platinum-refractory ovarian cancer: a randomized multicenter trial with SU11248 to evaluate dosage, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine k... | ||
Medical condition: Platinum refractory or resistant ovarian cancer, primary cancer of the peritoneum or fallopian tube (defined as stable (SD) or progressive disease (PD) during platinum containing chemotherapy, or ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-015904-24 | Sponsor Protocol Number: UKB-2009-MED-I-JKR-01 | Start Date*: 2010-10-20 |
Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn | ||
Full Title: An open, prospective study to compare the safety and efficacy of raltegravir vs. atazanavir / ritonavir, both in combination with tenofovir DF and emtricitabine, in the treatment of HIV-infection i... | ||
Medical condition: HIV disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003257-20 | Sponsor Protocol Number: 10MI28 | Start Date*: 2014-05-02 |
Sponsor Name:GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST | ||
Full Title: Evaluation of Treosulfan pharmacokinetics (PK) in children undergoing allogeneic haematopoietic stem cell transplantation (HSCT) | ||
Medical condition: Any paediatric disease with an indication to an allogeneic stem cell transplantation (inclusing leukaemia, primary immunodeficiencies, metabolic disorders and autoimmune or genetic inflammatory bow... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001198-55 | Sponsor Protocol Number: KronLungesyg_COVID_19_protokol_2 | Start Date*: 2020-04-03 | ||||||||||||||||
Sponsor Name:Chronic Obstructive Pulmonary Disease Trial Network (COP:TRIN) | ||||||||||||||||||
Full Title: Proactive Prophylaxis with Azithromycin and Hydroxychloroquine Patients Hospitalized with COVID | ||||||||||||||||||
Medical condition: This trial will investigate infection with coronavirus (COVID-19) in patients who are admitted to hospital | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003127-62 | Sponsor Protocol Number: MuSK-001 | Start Date*: 2015-10-02 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA | |||||||||||||
Full Title: A Randomized, Placebo-Controlled, Pilot Crossover Study to Evaluate the Effect of Amifampridine Phosphate (3,4-Diaminopyridine Phosphate) in Patients with MuSK Antibody Positive Myasthenia Gravis | |||||||||||||
Medical condition: Patients with MuSK Antibody Positive Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020063-21 | Sponsor Protocol Number: ILUVIT1 | Start Date*: 2010-06-15 | |||||||||||
Sponsor Name:Charité-Universitätsmedizin | |||||||||||||
Full Title: “A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis” | |||||||||||||
Medical condition: Urticarial vasculitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014844-13 | Sponsor Protocol Number: 50-2009 | Start Date*: 2010-03-16 |
Sponsor Name:Charité Universitätsmedizin Berlin | ||
Full Title: Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantat... | ||
Medical condition: Treatment ot mantle cell lymphoma patients in first or second relapse or refractory disease. Patients should not be eligible for high dose chemotherapy with autologous or allogenous stem cell trans... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-003553-42 | Sponsor Protocol Number: AIO-HEP-0217 | Start Date*: 2018-05-03 | ||||||||||||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | ||||||||||||||||||||||||||||
Full Title: A Phase II single-arm, open-label study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC) | ||||||||||||||||||||||||||||
Medical condition: intermediate stage hepatocellular carcinoma (HCC) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004963-32 | Sponsor Protocol Number: MPR-2 | Start Date*: 2005-07-18 |
Sponsor Name:Univ. Prof. Dr. Markus Peck-Radosavljevic | ||
Full Title: Bevacizumab (Avastin®) as inhibitor of collateral tumor vessel growth during transarterial chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC): a pilot trial | ||
Medical condition: Hepatocellular Carcinoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-004561-33 | Sponsor Protocol Number: ThromboAct | Start Date*: 2014-05-23 |
Sponsor Name:Medizinische Universität Wien, Klinik für Innere Medizin III, Abteilung für Gastroenterologie und Hepatologie | ||
Full Title: A randomized, controlled, single-blinded, phase II study to investigate the safety and efficacy of intravenous infusions of FERINJECT® versus placebo on platelet activity in patients with iron defi... | ||
Medical condition: iron deficiency in chronic inflammatory bowel disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-002095-18 | Sponsor Protocol Number: 107731 | Start Date*: 2007-03-20 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II randomized, double-blind (observer blind), adjuvant justification study of RTS,S/AS01B and RTS,S/AS02A, candidate malaria vaccines, administered according to a 0, 1, 2 months schedule in... | ||
Medical condition: Malaria disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006144-55 | Sponsor Protocol Number: ARD6123 [AVE0005B/2001] | Start Date*: 2007-03-14 |
Sponsor Name:sanofi-aventis recherche & développement | ||
Full Title: A multicenter, open-label, single-arm, two-stage study of the efficacy and safety of AVE0005 (VEGF Trap) administered intravenously every 2 weeks in patients with platinum- and erlotinib-resistant,... | ||
Medical condition: patients with platinum- and erlotinib-resistant, locally advanced or metastatic non-small-cell lung adenocarcinoma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-005463-10 | Sponsor Protocol Number: PLQ-001 | Start Date*: 2008-02-06 | |||||||||||
Sponsor Name:LEO Pharma A/S | |||||||||||||
Full Title: A plaque test comparing three marketed products and two products in development and a vehicle control for the treatment of psoriasis vulgaris | |||||||||||||
Medical condition: Psoriasis vulgaris lesions located on the arms, legs or trunk. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005487-13 | Sponsor Protocol Number: PLQ-002 | Start Date*: 2008-12-30 | |||||||||||
Sponsor Name:LEO Pharma A/S | |||||||||||||
Full Title: A plaque test comparing 4 steroids with Daivobet® ointment and a vehicle control for the treatment of psoriasis vulgaris | |||||||||||||
Medical condition: Psoriasis vulgaris lesions located on the arms, legs or trunk. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007888-24 | Sponsor Protocol Number: 0881X1-4508-FR | Start Date*: 2008-07-31 |
Sponsor Name:Wyeth Pharmaceuticals France | ||
Full Title: Open-label Study to Evaluate the EULAR-RAID Score, Rheumatoid Arthritis Impact of Disease Score, in Rheumatoid Arthritis Patients Eligible to Etanercept and Who Will Receive Etanercept. | ||
Medical condition: RHEUMATOID ARTHRITIS | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001012-68 | Sponsor Protocol Number: CA182-006 | Start Date*: 2007-04-17 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients... | |||||||||||||
Medical condition: Unresectable, advanced or metastatic hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
